Corrective Phases R...
Health Care: Drugs
Delcath Systems Inc. (DCTH: NASDAQ)
$1.46 0.02 | 1.39%
06/04/12 - 11:55 AM ET
Company Income Statement
| Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | |
| Sales | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Sales | -1.04M | -472.29K | -7.98K | -6.00K |
| Gross Operating Profit | 1.04M | 472.29K | 7.98K | 6.00K |
| Selling, General, and Administrative Expenses | 21.28M | 13.19M | 3.90M | 2.69M |
| Research & Development | 25.17M | 17.56M | 9.64M | 5.38M |
| Operating Income before D & A (EBITDA) | -45.42M | -30.27M | -13.53M | -8.06M |
| Depreciation & Amortization | 1.04M | 472.29K | 7.98K | 6.00K |
| Interest Income | 5.00K | 10.70K | 73.83K | 300.00K |
| Other Income - Net | 15.57M | -15.95M | -8.59M | 901.00K |
| Special Income / Charges | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Income Before Interest Expenses (EBIT) | -30.88M | -46.68M | -22.06M | -6.86M |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 |
| Pre-Tax Income | -30.88M | -46.68M | -22.06M | -6.86M |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Continuing Operations | -30.88M | -46.68M | -22.06M | -6.86M |
| Net Income From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Total Operations | -30.88M | -46.68M | -22.06M | -6.86M |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | -30.88M | -46.68M | -22.06M | -6.86M |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-30.88M | -46.68M | -22.06M | -6.86M |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | -30.88M | -46.68M | -22.06M | -6.86M |
| Basic EPS from Continuing Ops. | -0.68 | -1.20 | -0.82 | -0.27 |
| Basic EPS from Discontinued Ops. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Total Operations | -0.68 | -1.20 | -0.82 | -0.27 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | -0.68 | -1.20 | -0.82 | -0.27 |
| Basic Normalized Net Income/Share | -0.68 | -1.20 | -0.82 | -0.27 |
| EPS fr Continuing Ops. | -0.68 | -1.20 | -0.82 | -0.27 |
| EPS fr Discontinued Ops | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Total Ops. | -0.68 | -1.20 | -0.82 | -0.27 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS, Total | -0.68 | -1.20 | -0.82 | -0.27 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-0.68 | -1.20 | -0.82 | -0.27 |
| Dividends Paid per Share | 0.00 | 0.00 | 0.00 | 0.00 |
Portfolios with DCTH
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- UserROSIE
- UserTA stocks
- ContributorBarron's Activist Stocks 8-...
- UserSUPRATRADE 7 Top Stocks for...
- UserASCO 2010
- Contributor10 Biotech Stocks on Clinic...
- ContributorBarron's Insider Purchases ...
- User52 Week High Strategy
Latest DCTH Headlines from TheStreet
- BIO CEO Confab Live Blog: Day 2 02.14.12 | 10:02 am
- Biotech Stock Mailbag: Mela Sciences 09.09.11 | 06:09 am
- Biotech Calendar: Key Dates for September 08.31.11 | 06:08 am
- Biotech Stock Mailbag: Celsion 05.13.11 | 08:05 am
- 'Mad Money Lightning Round': Go for Exelixis 04.26.11 | 07:04 pm
- Biotech Stock Mailbag: Amarin 04.22.11 | 07:04 am
- Sweet Spot in Biotech Investing 04.13.11 | 12:04 pm
- Delcath: Safety Questions Behind FDA Delay 02.23.11 | 07:02 am
- Delcath Hit With FDA Approval Delay 02.22.11 | 10:02 am
- 10 Health Care Stocks With 100% Buy Ratings 01.28.11 | 07:01 am
Press Releases for DCTH
- Delcath Announces First CHEMOSAT Procedures In Germany - PR Newswire 02.27.12 | 06:02 am
- Delcath Announces Updated Efficacy Results From Phase 3 Trial Of Chemosaturation For Melanoma Metastases In The Liver Presented At European Multidisciplinary Cancer Congress - PR Newswire 09.23.11 | 06:09 pm
- Positive Phase 2 Trial Results From Neuroendocrine Tumor Cohort Presented At CIRSE - PR Newswire 09.13.11 | 02:09 am
- Delcath Systems Receives Refusal To File Letter From FDA - PR Newswire 02.22.11 | 05:02 am
- Delcath Achieves ISO 13485 Certification - PR Newswire 02.17.11 | 09:02 am
- Delcath Completes New Drug Application Submission To The FDA For The Chemosaturation Delivery System - PR Newswire 12.22.10 | 07:12 am
- Delcath Submits CE Mark Technical File For Hepatic ChemoSAT⢠Delivery System - PR Newswire 12.06.10 | 06:12 am
- Delcath Names Bernard R. Tyrrell As Senior Vice President For North American Sales And Marketing - PR Newswire 12.01.10 | 06:12 am
- Encompass Fund’s Go-Anywhere Strategy Continues To Excel In 2010 - Business Wire 11.10.10 | 05:11 pm
- Delcath Systems Announces Third Quarter Progress Report Conference Call - PR Newswire 10.27.10 | 06:10 am
Partner Headlines for DCTH
- Active Stock Alerts: Dendreon, Delcath Systems, Johnson & Johnson, Boeing, Onyx June 4th - Wall St. Cheat Sheet 06.04.12 | 10:06 am
- Hyper-Novel Investments For Targeting Cancer - Seeking Alpha 05.30.12 | 09:05 am
- Mid-Day Update: Stocks Trending Water Ahead of First Holiday Weekend of Summer - NASDAQ 05.25.12 | 04:05 pm
- Mid-Day Market Losers - Benzinga 05.25.12 | 01:05 pm
- 4 Stocks Attracting Heavy Trading Interest - Wall St. Cheat Sheet 05.25.12 | 12:05 pm
- Ultimate Market Recap: Talbots Tanks, Facebook Fiasco Continues - Wall St. Cheat Sheet 05.25.12 | 06:05 am
- Company News for January 03, 2012 - Corporate Summary - Zacks 01.03.12 | 10:01 am
- Emisphere: Crown Jewel In Oral B12 - Seeking Alpha 10.07.11 | 09:10 am
- Delcath Announces Updated Efficacy Results from Phase 3 Trial of Chemosaturation for Melanoma Metastases in the Liver - Benzinga 09.23.11 | 06:09 pm
- Friday's Top Performing Small Cap Stocks (MDS, MNKD, FXCM, FOE, DCTH) - NASDAQ 08.15.11 | 01:08 pm
